In earlier experiments it has been shown that cellular cytotoxicity of patients with prostatic carcinoma (CaP) as measured by cytolysis of EB 33 target cells correlates with the extent of their tumor lesion: a high grade of cytotoxicity was observed only when CaP was confined to gland. In order to define a possible in vivo immunological host-tumor interaction, further characterization of the type of effector cell responsible for in vitro killing has been attempted. Effector cells could be either tumor-specific sensitized T cells, K cells, macrophages or NK cells. Antibody-dependent K-cell activity could most likely be excluded, since autologous and homologous serum did not affect the extent of EB 33 killing when added to the test medium. Further separation of effector cells by nylon wool columns resulted in increased cytolysis of EB 33 target cells. This can be due either to tumor-specific T-cell-mediated mechanisms or to an increased natural killer cell activity, as macrophages and B cells were significantly removed by this measure. Separation of T and NK cells is necessary to ascertain the effector cell responsible for the in vitro killing of tumor cells derived from human CaP.

Keywords:
Tumorimmunology, Cell-mediated cytotoxicity, Prostatic carcinoma, Effector cells
This content is only available via PDF.
© 1981 S. Karger AG, Basel
1981
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.